Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8NFU5
UPID:
IPMK_HUMAN
Alternative names:
Inositol 1,3,4,6-tetrakisphosphate 5-kinase
Alternative UPACC:
Q8NFU5
Background:
Inositol polyphosphate multikinase, also known as Inositol 1,3,4,6-tetrakisphosphate 5-kinase, plays a pivotal role in cellular processes by phosphorylating various inositol phosphates. This enzyme's activity is crucial for the production of inositol 1,3,4,5,6-pentakisphosphate and inositol hexakisphosphate, compounds essential for cellular signaling and homeostasis.
Therapeutic significance:
Understanding the role of Inositol polyphosphate multikinase could open doors to potential therapeutic strategies. Its involvement in MLKL-mediated necroptosis highlights its significance in cell death pathways, suggesting avenues for intervention in diseases where necroptosis is implicated.